No Data
No Data
Foghorn Therapeutics Announces New Preclinical Data at AACR
Foghorn Therapeutics Advances FHD-909 in Phase 1 Trial for SMARCA4 Mutated Cancers With Promising Preclinical Data for Combination Therapies
Flagship Pioneering Unveils Etiome to Pioneer Preemptive Healthcare
JMP Securities Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $9
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday
JMP Securities Initiates Coverage On Foghorn Therapeutics With Market Outperform Rating, Announces Price Target of $9